{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:34:40Z","timestamp":1794584080160,"version":"4.9.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230792-4\"><jats:title>Importance<\/jats:title><jats:p>Patients with mesothelioma often have next-generation sequencing (NGS) of their tumor performed; tumor-only NGS may incidentally identify germline pathogenic or likely pathogenic (P\/LP) variants despite not being designed for this purpose. It is unknown how frequently patients with mesothelioma have germline P\/LP variants incidentally detected via tumor-only NGS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230792-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence of incidental germline P\/LP variants detected via tumor-only NGS of mesothelioma.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230792-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A series of 161 unrelated patients with mesothelioma from a high-volume mesothelioma program had tumor-only and germline NGS performed during April 2016 to October 2021. Follow-up ranged from 18 months to 7 years. Tumor and germline assays were compared to determine which P\/LP variants identified via tumor-only NGS were of germline origin. Data were analyzed from January to March 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230792-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The proportion of patients with mesothelioma who had P\/LP germline variants incidentally detected via tumor-only NGS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230792-8\"><jats:title>Results<\/jats:title><jats:p>Of 161 patients with mesothelioma, 105 were male (65%), the mean (SD) age was 64.7 (11.2) years, and 156 patients (97%) self-identified as non-Hispanic White. Most (126 patients [78%]) had at least 1 potentially incidental P\/LP germline variant. The positive predictive value of a potentially incidental germline P\/LP variant on tumor-only NGS was 20%. Overall, 26 patients (16%) carried a P\/LP germline variant. Germline P\/LP variants were identified in <jats:italic>ATM<\/jats:italic>, <jats:italic>ATR<\/jats:italic>, <jats:italic>BAP1<\/jats:italic>, <jats:italic>CHEK2, DDX41<\/jats:italic>, <jats:italic>FANCM<\/jats:italic>, <jats:italic>HAX1<\/jats:italic>, <jats:italic>MRE11A<\/jats:italic>, <jats:italic>MSH6<\/jats:italic>, <jats:italic>MUTYH<\/jats:italic>, <jats:italic>NF1<\/jats:italic>, <jats:italic>SAMD9L<\/jats:italic>, and <jats:italic>TMEM127<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230792-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this case series of 161 patients with mesothelioma, 16% had confirmed germline P\/LP variants. Given the implications of a hereditary cancer syndrome diagnosis for preventive care and familial counseling, clinical approaches for addressing incidental P\/LP germline variants in tumor-only NGS are needed. Tumor-only sequencing should not replace dedicated germline testing. Universal germline testing is likely needed for patients with mesothelioma.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.27351","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:02:02Z","timestamp":1691593322000},"page":"e2327351","source":"Crossref","is-referenced-by-count":21,"title":["Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma"],"prefix":"10.1001","volume":"6","author":[{"given":"Owen D.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gilliam","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"del Gaudio","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey E.","family":"McNeely","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaili","family":"Smith","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Acevedo","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Gaduraju","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hodge","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrianna S. S.","family":"Ramsland","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feighanne","family":"Hathaway","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren S.","family":"Bryan","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjukta","family":"Tawde","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Galasinski","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Y.","family":"Tjota","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya N.","family":"Husain","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel G.","family":"Armato","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Donington","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Churpek","sequence":"additional","affiliation":[{"name":"Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Drazer","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"zoi230792r1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"zoi230792r2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tranon.2014.12.002","article-title":"Changing pattern in malignant mesothelioma survival.","volume":"8","author":"Faig","year":"2015","journal-title":"Transl Oncol"},{"issue":"18","key":"zoi230792r3","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"zoi230792r4","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma.","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"zoi230792r5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett"},{"issue":"4","key":"zoi230792r6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jtho.2019.12.111","article-title":"Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas.","volume":"15","author":"Guo","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"35","key":"zoi230792r7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations.","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230792r8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"zoi230792r9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations.","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"2","key":"zoi230792r10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi230792r11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"issue":"4","key":"zoi230792r12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"11","key":"zoi230792r13","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma.","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"zoi230792r14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/(ISSN)1098-1004","article-title":"Familial melanoma, pancreatic cancer and germline CDKN2A mutations.","volume":"23","author":"Goldstein","year":"2004","journal-title":"Hum Mutat"},{"issue":"23","key":"zoi230792r15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"issue":"9679","key":"zoi230792r16","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2.","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"zoi230792r17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14153664","article-title":"Li-Fraumeni Syndrome: mutation of TP53 is a biomarker of hereditary predisposition to tumor: new insights and advances in the treatment.","volume":"14","author":"Rocca","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"zoi230792r18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ajhg.2015.07.004","article-title":"Mutations in DDX3X are a common cause of unexplained intellectual disability with gender-specific effects on Wnt signaling.","volume":"97","author":"Snijders Blok","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"5","key":"zoi230792r19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"zoi230792r20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","article-title":"Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays.","volume":"19","author":"Kadri","year":"2017","journal-title":"J Mol Diagn"},{"issue":"5","key":"zoi230792r21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"10272","key":"zoi230792r22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"zoi230792r23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41525-021-00224-6","article-title":"Incidental findings from cancer next generation sequencing panels.","volume":"6","author":"Maani","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"2","key":"zoi230792r24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"zoi230792r25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ijc.v136.7","article-title":"Tumor genome analysis includes germline genome: are we ready for surprises?","volume":"136","author":"Catenacci","year":"2015","journal-title":"Int J Cancer"},{"issue":"35","key":"zoi230792r26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00328","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing.","volume":"36","author":"Slavin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230792r27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10689-020-00192-3","article-title":"Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series.","volume":"20","author":"Scott","year":"2021","journal-title":"Fam Cancer"},{"issue":"5","key":"zoi230792r28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/annonc\/mdw018","article-title":"Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.","volume":"27","author":"Meric-Bernstam","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi230792r29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/gim.2013.73","article-title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.","volume":"15","author":"Green","year":"2013","journal-title":"Genet Med"},{"issue":"10","key":"zoi230792r30","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.29951","article-title":"Patient preferences regarding incidental genomic findings discovered during tumor profiling.","volume":"122","author":"Yushak","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"zoi230792r31","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.2013.52.4298","article-title":"Physicians\u2019 attitudes about multiplex tumor genomic testing.","volume":"32","author":"Gray","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi230792r32","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1200\/JCO.21.02764","article-title":"Point\/counterpoint: is it time for universal germline genetic testing for all GI cancers?","volume":"40","author":"Hampel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi230792r33","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000414","article-title":"Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study.","volume":"12","author":"Uson","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"zoi230792r34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JOP.19.00201","article-title":"When should tumor genomic profiling prompt consideration of germline testing?","volume":"15","author":"DeLeonardis","year":"2019","journal-title":"J Oncol Pract"},{"issue":"5","key":"zoi230792r35","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.7314\/APJCP.2012.13.5.2051","article-title":"The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"zoi230792r36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/dna.2013.1970","article-title":"The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis.","volume":"32","author":"Han","year":"2013","journal-title":"DNA Cell Biol"},{"issue":"1","key":"zoi230792r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808123\/mitchell_2023_oi_230792_1690824021.8693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:02:05Z","timestamp":1691593325000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27351","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}